The AHA March 3 urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk ...

On February 2, 2024, the “gang of six”—a bipartisan group of six senators who have traditionally championed reforms to the 340B program 1 —introduced a discussion draft of a bill that would modify the ...

Feds back AbbVie Colorado 340B fight, arguing state law conflicts with federal 340B program in a key 10th Circuit appeal.

The Tungsten+PLUS™ platform delivers comprehensive downstream services, including MFP claims reconciliation, dispute resolution, and compliance-ready workflows. The platform provides Health Systems ...

A new report paints a stark picture of how a subset of large healthcare providers are drawing the lion’s share of 340B savings within a single state.  | A Minnesota analysis of providers' reported ...

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

In a move that will fundamentally change how the 340B Drug Pricing Program (“340B Program”) operates for a subset of medications, HRSA’s Office of Pharmacy Affairs (“OPA”) opted late last week to ...

In August, J&J informed disproportionate share hospitals, which care for a large number of vulnerable patients, that it would stop giving them upfront discounts on plaque psoriasis treatment Stelara ...

Hospitals and clinics in Michigan participating in a federal drug discount program are marking up medications and shifting costs onto public employee health plans, according to ...

Amid ongoing controversy over 340B drug discounts, a sweeping review suggests the program is doing what it was intended to do: generate revenue for hospitals, clinics and pharmacies by requiring ...

Congress needs to act to bring needed reforms into the 340B to make revenue from the drug pricing program more transparent and to ensure patients are benefiting from the discounts, according to a ...